NCT00071097 - TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

November 30, 2007

Conditions

HIV Infections

Interventions

DRUG

TMC114/rtv

800mg TMC114/100mg rtv once daily

DRUG

TMC114/rtv

400mg TMC114/100mg rtv both twice daily

DRUG

TMC114/rtv

400mg TMC114/100mg rtv once daily

DRUG

TMC114/rtv

600mg TMC114/100mg rtv twice daily

Trial Locations (39)

Unknown

Birmingham

Phoenix

Beverly Hills

Long Beach

Los Angeles

Oakland

San Diego

San Francisco

West Hollywood

Denver

Washington D.C.

Altamonte Springs

Fort Lauderdale

Miami

Miami Beach

Tampa

Vero Beach

Atlanta

Macon

Chicago

Baltimore

Boston

Springfield

Camden

Albany

New York

Huntersville

Cincinnati

Cleveland

Hershey

Philadelphia

Columbia

Dallas

Galveston

Houston

Hampton

Seattle

Milwaukee

Buenos Aires

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY